Latest PFE news

These 6 High-Yield Dividends May Be Too Good to Be True

24/7 Wall Street · Wed, 23 Sep 2026 13:25:42 -0400

A fat dividend yield can signal a screaming buy or a slow-motion disaster, and the difference hides in coverage math most investors never check.

Viking's Obesity Edge May Be Staying Power, Not Weight Loss

MarketBeat · Wed, 23 Sep 2026 13:22:25 -0400

Viking Therapeutics NASDAQ: VKTX stock jumped 36% on Sept. 22. The catalyst was new maintenance data for VK2735, its GLP-1/GIP obesity candidate, which showed that patients maintained most of their weight loss after switching from weekly shots to every-other-week or monthly dosing.

Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year

24/7 Wall Street · Wed, 23 Sep 2026 11:32:35 -0400

Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.

4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout

24/7 Wall Street · Wed, 23 Sep 2026 09:01:41 -0400

Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions.

3 Dividend Stocks Trading Cheap Enough to Buy Meaningful Stakes for Under $1,000

24/7 Wall Street · Wed, 23 Sep 2026 08:00:49 -0400

AT&T, Verizon, and Pfizer all trade under $50 a share, but a low entry price and genuine value are two very different things, and only one of these three high-yield names carries a coverage story that should make income investors

Pfizer, Kraft, and UPS All Yield More Than 6%. Which of These Dividend Stocks Is the Safest Option Today?

The Motley Fool · Wed, 23 Sep 2026 05:00:01 -0400

Pfizer, UPS, and Kraft are all high-yielding stocks that come with varying levels of risk. They're all generating positive free cash flow, but their payout ratios don't look good.

Pfizer: A Quietly Outperforming High-Dividend Idea, Pipeline On Watch (Upgrade)

Seeking Alpha · Tue, 22 Sep 2026 21:27:46 -0400

Pfizer is upgraded to buy, supported by a low valuation, strong free cash flow, and a high 6.2% dividend yield. PFE delivered a Q2 double beat, raised full-year revenue guidance, and benefits from pipeline progress, though COVID-19 product sales guidance was trimmed. Technical momentum is building, with a golden cross and bullish rounded bottom pattern, but resistance remains near $30.

Market information is provided for research and visualization and is not investment advice.